Search Results for "R"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for R. Results 591 to 600 of 1003 total matches.
Tofersen (Qalsody) for ALS
The Medical Letter on Drugs and Therapeutics • Jul 24, 2023 (Issue 1681)
to week 28
in total score on the ALS Functional Rating Scale-
Revised (ALSFRS-R; range 0-48, with higher ...
Tofersen (Qalsody – Biogen), an intrathecally
administered antisense oligonucleotide, has received
accelerated approval from the FDA for treatment of
amyotrophic lateral sclerosis (ALS) in adults who
have a mutation in the superoxide dismutase 1
(SOD1) gene. About 2% of patients with ALS have
mutations in the SOD1 gene. Tofersen is the first drug
to be approved in the US that targets a genetic cause
of ALS. Accelerated approval of the drug was based
on the surrogate endpoint of a reduction in plasma
neurofilament light chain, which is considered likely
to predict clinical...
Med Lett Drugs Ther. 2023 Jul 24;65(1681):113-4 doi:10.58347/tml.2023.1681a | Show Introduction Hide Introduction
Adult Immunization
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022 (Issue 1661)
Td4 44.80
Booster dose of Td or Tdap every 10 years
Measles, Mumps, Rubella (MMR)
M-M-R II (Merck)6 ...
The Advisory Committee on Immunization Practices
(ACIP) recommends use of certain vaccines in adults
residing in the US. Routine childhood immunization
has reduced the overall incidence of some of
these vaccine-preventable diseases, but many
adults remain susceptible. Recommendations for
vaccination against COVID-19, seasonal influenza,
and monkeypox and vaccination of travelers have
been reviewed separately.
Antiviral Drugs for Seasonal Influenza for 2025-2026
The Medical Letter on Drugs and Therapeutics • Oct 27, 2025 (Issue 1740)
resistance
during the 2018-2019 influenza season. J Infect 2019; 79:612.
37. R Roosenhoff et al. Viral ...
Influenza is generally a self-limited illness, but complications
including pneumonia, respiratory failure, and
death can occur, especially in persons at increased
risk (see Table 1).
Med Lett Drugs Ther. 2025 Oct 27;67(1740):169-74 doi:10.58347/tml.2025.1740a | Show Introduction Hide Introduction
Diclofenac
The Medical Letter on Drugs and Therapeutics • Dec 02, 1988 (Issue 780)
) for treatment of
rheumatoid arthritis and osteoarthritis (J Zuckner, Am J Med, 80 suppl 4B:39, 1986; R Altman ...
Diclofenac sodium (Voltaren - Geigy), a nonsteroidal anti-inflammatory drug (NSAID) available in some countries since 1974, was recently introduced in the USA for treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. It is being promoted as 'The number one prescribed antiarthritic in the world.'
Aspirin For Prevention Of Myocardial Infarction And Stroke
The Medical Letter on Drugs and Therapeutics • Aug 25, 1989 (Issue 799)
no statistically significant difference in the incidence of myocardial infarction or stroke
(R Peto et al, Br Med ...
Taking aspirin to prevent recurrence or worsening of cardiovascular disease has become a common practice in recent years (Medical Letter, 28:31, 1986). Now, the US Food and Drug Administration is considering whether aspirin can also be advertised for prevention of a first myocardial infarction in previously healthy people.
Omeprazole
The Medical Letter on Drugs and Therapeutics • Mar 09, 1990 (Issue 813)
metabolized by the liver (R Gugler and JC
Jensen, Gastroenterology, 89:1235, 1985), but whether ...
Omeprazole (Losec - Merck), a new drug that suppresses gastric acid secretion, has been approved by the US Food and Drug Administration for short-term (four to eight weeks) treatment of severe or refractory gastroesophageal reflux and for long-term treatment of pathological hypersecretory conditions such as Zollinger-Ellison syndrome, multiple endocrine adenomas, and systemic mastocytosis. Although widely used abroad for treatment of peptic ulcers, it has not been approved for that indication in the USA.
Clarithromycin and Azithromycin
The Medical Letter on Drugs and Therapeutics • May 15, 1992 (Issue 870)
infections (TM Hooton, Am J Med, 91 suppl 3A:23S, 1991; RR Casiano,
Am J Med, 91 suppl 3A:27S, 1991; R Kiani ...
Clarithromycin (Biaxin - Abbott) and azithromycin (Zithromax - Pfizer), two macrolide antibiotics chemically related to erythromycin, have been approved by the US Food and Drug Administration for treatment of respiratory, skin, and skin structure infections. Azithromycin has also been approved for treatment of nongonococcal urethritis and cervicitis caused by Chlamydia trachomatis.
Zaleplon for Insomnia
The Medical Letter on Drugs and Therapeutics • Oct 08, 1999 (Issue 1063)
more than zaleplon (R
Elie et al, J Clin Psychiatry, 60:536, August 1999). A pharmacodynamic study ...
Zaleplon, a pyrazolopyrimidine hypnotic, was recently approved by the FDA for short-term treatment of insomia. Zaleplon, like zolpidem, is a non-benzodiazepine that binds to benzodiazepine receptors.
Erythropoietin (Procrit; Epogen) Revisited
The Medical Letter on Drugs and Therapeutics • May 14, 2001 (Issue 1104)
. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS: Mathew Maurer, M.D., Columbia ...
Use of epoetin alfa, a recombinant human erythropoietin, is being promoted directly to consumers in vague advertisements that promise renewed energy and improved work capacity. Epoetin is approved by the FDA for treatment of anemia due to chronic renal failure, cancer chemotherapy or HIV treatment, and before elective non-cardiac surgery. It is also used illicitly by competitive athletes to increase their endurance.
Ziprasidone (Geodon) For Schizophrenia
The Medical Letter on Drugs and Therapeutics • Jun 11, 2001 (Issue 1106)
, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University ...
Ziprasidone (Geodon - Pfizer), a benzisothiazolyl piperazine, has been approved by the FDA for oral treatment of schizophrenia. An intramuscular formulation will probably be available in the near future.
